康方生物:IL-4R抗体申报上市

医药笔记
Feb 25

▎Armstrong2026年2月25日,康方生物IL-4R抗体曼多奇单抗注射液的上市申请获得NMPA受理。2025年8月,康方生物宣布IL-4R抗体曼多奇单抗治疗中重度特应性皮炎的三期临床达到全部疗效终点,拟申报上市。基于研究间比较(非头对头),曼多奇单抗疗效数据优于已上市产品Dupixent,后续还在扩展至青少年人群。赛诺菲IL-4R抗体Dupixent为全球范围内最畅销的自免药物,2025...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10